7 Month 11 Day, in “Biotechnology Industry Science and Technology Innovation and Transformation Salon” Above, Laien Bio (Lion TCR）and Sino-Singapore International Joint Research Institute （CSIRI) officially signed a strategic cooperation agreement.This collaboration will integrate the strengths of both parties in biomedicine R&D, achievement transformation, and international resource linkage, jointly promoting cell therapy,mRNAInnovative breakthroughs in cutting-edge fields such as nucleic acid technology, building “Industry-University-Research Collaboration” A collaborative innovation ecosystem injects strong momentum into the biomedicine industry development in both China and Singapore as well as in the Guangdong-Hong Kong-Macao Greater Bay Area.At the event, Dr. Ma Yifan, Chief Scientific Officer of Guangzhou Laien Biological Medicine Co., Ltd., attended the signing ceremony and delivered a speech, sharing insights from Laien Biological Medicine.mRNACodingTCR-TLatest Advances in Cell Therapy Research.

Dr. Yifan Ma (second from the left), Chief Scientific Officer, represented Guangzhou Laien Biological Medicine Co., Ltd. at the event.

Signing of Strategic Cooperation Agreement with Sino-Singapore International Joint Research Institute

Deepening Cooperation in Four Key Dimensions to Build a Transnational Innovation Ecosystem

According to the strategic cooperation agreement, the two parties will deepen collaboration in four major directions: with the China-Singapore International Joint Research InstituteRelying on the Biotechnology Application Concept Validation Center and combining the advantages of Laien Biotherapeutics' cell therapy technology, we will jointly tackle cutting-edge fields such as novel cell therapies, accelerating technology transfer and market expansion; linking up with international resources in the Guangdong-Hong Kong-Macao Greater Bay Area and Singapore to build a two-way technology transfer center and construct a cross-border innovation ecosystem; integrating spatial and industrial resources, co-organizing roadshow forums, building resource exchange and talent docking platforms, and activating... “Industry-University-Research Collaboration” Kinetic energy; at the same time, leveraging both parties' promotional channels for joint promotion, enhancing industry influence, and jointly building a cross-border biomedical innovation ecosystem.

Dr. Yifan Ma, Chief Scientific Officer of Guangzhou Laien Biological Medicine Co., Ltd., Shares Latest Advances in mRNA-Encoded TCR-T Cell Therapy Research

Dr. Ma Yifan: Building an Innovative Bridge for Biomedical Collaboration Between China and Singapore

Dr. Yifan Ma, Chief Scientific Officer of Guangzhou Laien Biological Medicine Co., Ltd., shared at this event.mRNAEncodingTCR-TLatest Advances in Cell Therapy Research.

In terms of product development, Guangzhou Laien Biological Medicine Co., Ltd. relies on itsmRNATechnology andAIEmpoweredTCRNew Target Discovery Platform, willTCR-TThe product pipeline has been expanded to treat various solid tumors, such as lung cancer, breast cancer, and gastrointestinal tumors, providing innovative therapies for unmet clinical needs. Meanwhile, the company has established an off-the-shelf therapy product platform, utilizingmRNA-LNPDelivery Technology Implementationin vivo TCR-TTreatment, greatly reducing the cost of the product. Currently, the leading product of Laien BioHBV TCR-TCells, Focused on Liver Cancer Treatment, Are the World's FirstFDAApproved UseHBV TCR-TInternational Multicenter Therapy for Liver Cancer2Phase clinical trial, obtainedFDADual Qualifications of Fast Track and Orphan Drug.2024Year11In the month, Guangzhou Laien Biological Medicine Co., Ltd. received approval from the China National Medical Products Administration.NMPATheINDTacit consent marks the company inTCR-TImportant Advances in the Field of Cell Therapy.

Speaking about the cooperation with the Sino-Singapore International Joint Research Institute this time, Dr. Ma Yifan said:“The profound accumulation of the China-Singapore International Joint Research Institute in interdisciplinary research and achievement transformation perfectly complements Guangzhou Laien Biological Medicine Co., Ltd.'s clinical R&D capabilities and international resource layout. It is expected that this cooperation will build a bridge for biomedical innovation between China and Singapore, allowing more breakthrough therapies to benefit patients more quickly.”

This strategic cooperation marks that Guangzhou Laien Biological Medicine Co., Ltd. and the China-Singapore International Joint Research Institute will use Guangzhou as a fulcrum to connect with Singapore's innovative resources, injecting new momentum for high-quality development of the biomedicine industry in the Guangdong-Hong Kong-Macao Greater Bay Area through international collaboration, jointly writing a new chapter. “Integration of Industry, Academia, Research, and Application” A New Chapter of Collaborative Innovation.

Highlights:

Laien Biomedical Shines at the 2025 Singapore RNA Therapeutics Development Initiative RNA Symposium: mRNA Technology Drives New Breakthroughs in Cancer Treatment

Major Breakthrough! Laien Bio's Liocyx-M004 Approved by FDA for International Multicenter Phase 2 Clinical Trial in Liver Cancer Treatment

World's First! Laien Bio's mRNA-Encoded TCR-T Approved for Clinical Trials, Precisely Targeting Hepatocellular Carcinoma

Guangzhou Laien Biological Medicine Co., Ltd. Honored as "2024 Hurun China Emerging Medical Enterprise"

Innovation-Driven! Guangzhou Laien Biological Medicine Co., Ltd. Honored with "Third Prize in the Finals of the 13th China Innovation and Entrepreneurship Competition (Guangdong · Guangzhou Division)"

LIONTCR

WeChat ID｜Laien Bio

Official Website｜https://www.liontcr.com/